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Abstract
Background: Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept)
is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of
this study was to evaluate the in-vitro effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts
isolated from the same SSc patient.
Methods: Circulating fibrocytes and skin fibroblasts were obtained from eight SSc patients with “limited” cutaneous
involvement and from four healthy subjects (HSs). Samples were analyzed by fluorescence-activated cell sorter
analysis (FACS) at baseline (T0) and after 8 days of culture (T8) for CD45, collagen type I (COL I), CXCR4, CD14, CD86,
and HLA-DRII expression. Circulating fibrocytes were treated for 3 h and skin fibroblasts for 24/48 h with CTLA4-Ig
(10, 50, 100, 500 μg/ml). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed for CD86, COL I,
FN, TGFβ, αSMA, S100A4, CXCR2, CXCR4, CD11a, and Western blotting was performed for COL I and FN.
Results: Using qRT-PCR, the T8-cultured SSc circulating fibrocytes which had not been treated with CTLA4-Ig
showed higher gene expression for CD86, αSMA, S100A4, TGFβ, and COL I compared with HS circulating fibrocytes.
Interestingly, αSMA/COL I gene expression was significantly lower only in the SSc circulating fibrocytes treated with
CTLA4-Ig for 3 h (p < 0.01, p < 0.05). On the contrary, no effects were observed for either SSc or HS skin fibroblasts
after CTLA4-Ig treatment. COL I and FN protein expression was unchanged in both SSc and HS skin fibroblasts by
Western blot.
Conclusions: Circulating fibrocytes seem to be more responsive to CTLA4-Ig treatment than skin fibroblasts from
the same SSc patient, likely due to their higher expression of CD86. CTLA4-Ig treatment might downregulate the
fibrotic process in SSc patients by downregulating the fibrocytes, circulating progenitor cells.
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Key messages
Circulating fibrocytes seem to be more responsive to
CTLA4-Ig (abatacept) treatment than skin fibroblasts
isolated from the same SSc patients affected by limited
or diffuse cutaneous involvement.
The described effetct exerted by abatacept may
represent a new approach for early intervention in
SSc, therefore acting on progenitor cells (fibrocytes)
before their final homing and differentiation into
active myofibroblasts.
A new therapeutic option for abatacept in SSc treatment
should be taken into consideration based on its possible
antifibrotic effect.
Background
Systemic sclerosis (SSc) is a systemic autoimmune con-
nective tissue disease of complex etiology, characterized
by microvasculopathy and progressive fibrosis [1, 2].
Activation of the immune response through autoanti-
body production, together with the recruitment and
transition of endothelial cells and pericytes into active
myofibroblasts, seems to play an important role in the
progression of fibrosis in almost all organs. Therefore,
although the pathogenesis of SSc remains unclear, myo-
fibroblast activation is believed to be the final step fol-
lowing microvascular damage [3, 4]. Myofibroblasts are
characterized by a higher expression of specific pheno-
type markers and profibrotic molecules, primarily
α-smooth muscle actin (αSMA) and fibroblast-specific
protein-1 (S100A4), as well as by the overproduction of
extracellular matrix (ECM) proteins such as fibronectin
(FN) and fibrillar collagens (type I and III) [5–7].
Various cell types, including endothelial cells, circulat-
ing mesenchymal cells, and even fibrocytes, may differ-
entiate into myofibroblasts [8].
Fibrocytes are circulating progenitor cells derived from
the bone marrow that express specific markers of both
hematopoietic cells (CD34, CD43, CD45, LSP-1, and
MHC class II) and stromal cells (collagen I and III),
together with the chemokine receptors CCR2, CCR7, and
CXCR4, which regulate their migration into inflammatory
lesions [9–13]. Circulating fibrocytes are recruited
through CXCR4/CXCL12 interaction into injured tissues
where they differentiate into fibroblasts/myofibroblasts,
thereby regulating the healing process (by producing cyto-
kines, chemokines, and growth factors), secreting essential
ECM proteins, and promoting angiogenesis [14–16].
Moreover, although fibrocytes are involved in physio-
logical wound repair to local tissue injury, in chronic
fibroproliferative disorders they may be the cause of
excess deposition of ECM molecules [17].
In vitro, fibrocytes appear to differentiate from circulat-
ing CD14+ monocytes into spindle-shaped, fibroblast-like
cells and seem to have an antigen-presenting capability,
expressing class II major histocompatibility complex mol-
ecules (HLA-DP, -DQ, and -DR), the CD86 (B7.2) costi-
mulatory molecule, and the CD11a, CD54 (ICAM-1:
intracellular adhesion molecule-1), and CD58 adhesion
molecules [9, 18–20]. When cultured in the presence of a
specific antigen, human fibrocytes induce antigen-presenting
cell (APC)-dependent T-cell proliferation which is
significantly higher than that induced by monocytes
and nearly as high as the proliferation of purified
dendritic cells [20].
The costimulatory molecule CD86 is expressed on
APCs, including macrophages, and the CTLA4-Ig fusion
protein induces a significant downregulation of both
proinflammatory cytokines (interleukin (IL)-6, tumor ne-
crosis factor (TNF)α, and IL-1β) and transforming
growth factor (TGF)β in cultured human macrophages
[21]. Of note, these anti-inflammatory effects induced by
the binding between CTLA4-Ig and CD86 on the
macrophage surface are evident both in the presence
and in the absence of T cells, indicating a direct action
of CTLA4-Ig on APCs [21–23].
In addition, CTLA4-Ig interacts with the costimula-
tory molecule CD86 on human endothelial cells, mask-
ing its expression and modulating the expression of
vascular endothelial growth factor receptor (VEGFR)-2
and ICAM-1, two important molecules involved in in-
flammatory and angiogenic processes that characterize
several autoimmune diseases, including SSc [24].
Current treatment for SSc includes vasodilators,
disease-modifying antirheumatic drugs (DMARDs), and
immunosuppressive drugs, but with limited success.
New approaches for the treatment of SSc and its fibro-
tizing processes are under investigation, including the
use of CTLA4-Ig (abatacept) [25–27].
Since human fibrocytes seem to have an antigen-
presenting capability, and would appear to be an
important source of fibroblasts/myofibroblasts in the
physiological and pathological tissue remodeling that
characterizes SSc, the aim of this study was to isolate
and culture human circulating fibrocytes and skin
fibroblasts from the same SSc patients as well as from
healthy subjects (HSs) to investigate the possible
effects exerted in vitro by CTLA4-Ig treatment.
Methods
SSc patients and healthy subjects
Eight SSc patients (seven females and one male, mean
age 65 ± 7 years) with “limited” cutaneous involvement
(lSSc) and an “active” nailfold videocapillaroscopic
(NVC) pattern of microvascular damage were recruited
from the Division of Rheumatology at the University of
Genova. Four age-matched HSs (three females, one
male) were enrolled from the Department of Surgery of
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the IRCCS San Martino Hospital in Genoa during
routine diagnostic procedures.
All enrolled SSc patients fulfilled the 2013 European
League Against Rheumatism/American College of
Rheumatology (EULAR/ACR) criteria for the diagnosis of
SSc [28]. No evident clinical SSc complications were
present at the time of skin sampling, and the patients were
receiving treatment with vasodilators alone (mainly cyclic
prostanoids). At the site of skin biopsy (forearm), the local
average value of the modified Rodnan skin score (mRSS)
was found to be equal to 1 [29].
All SSc patients and HSs provided informed consent
and the study was approved by the local ethics committee
(protocol number 273-REG-2015).
Cell culture and treatments
Fibrocytes were isolated from the peripheral blood
mononuclear cells (PBMCs) by centrifugation over
Ficoll-Paque (Sigma-Aldrich) according to the manufac-
turer’s instructions. The cells were cultured at baseline
(T0) on fibronectin-coated plates in Dulbecco’s modified
Eagle’s medium (DMEM) with 20% fetal bovine serum
(FBS), 1% penicillin-streptomycin, and 1% L-glutamine
(Sigma-Aldrich) at 37 °C and 5% of CO2. After overnight
culture, the nonadherent cells were removed by a single
gentle aspiration, while adherent fibrocytes were cultured
for a further 8 days (T8) [30].
Fibrocytes at T8 were cultured for 3 h with or without
CTLA4-Ig at various concentrations (10, 50, 100, and
500 μg/ml) in accordance with previous in-vitro studies
[21, 22, 24].
Skin fibroblasts were isolated from the full thickness
biopsies that had been carried out on the involved skin
at one-third of the distal forearm of SSc patients and of
HSs, in accordance with the EUSTAR protocol and the
Declaration of Helsinki [31].
After fibroblast expansion, skin fragments were
removed to allow cell growth. Fibroblasts that were
collected between the third and fifth culture passage
were cultured for 24 and 48 h in the absence or in the
presence of various concentrations of CTLA4-Ig (10, 50,
100, and 500 μg/ml).
Fluorescence-activated cell sorter (FACS) analysis
After 8 days of culture (T8), adherent fibrocytes were
lifted by incubation in ice-cold 0.05% EDTA in
phosphate-buffered saline (PBS), and cell viability was
determined by the trypan blue exclusion test.
Characterization and identification of fibrocytes was
performed at T0 and T8 by FACS (Beckman Coulter
Company) using anti-CD45 (anti-CD45-krome orange,
Beckman Coulter Company), anti-COL I (anti-COL I-FITC,
Milli-Mark, Millipore), anti-CXCR4 (anti-CXCR4-PE,
Beckman Coulter Company), anti-CD14, anti-CD86, and
anti-HLA-DRII monoclonal antibodies (anti-CD14-alexa
Fluor 750, anti-CD86-PC7, and anti-HLA-DRII-PC5.5,
Beckman Coulter Company) [30].
Relevant isotype controls for each monoclonal antibody
were used in the initial setup and frequently between tests.
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Fibrocytes were cultured for 8 days whereas skin fibro-
blasts were cultured up to 80% confluency prior to treat-
ment with CTLA4-Ig, as described in the “Cell culture
and treatments” section above.
Total RNA was extracted with NucleoSpin RNA/pro-
tein (Macherey-Nagel) and quantified by NanoDrop
(Thermo Scientific), which also evaluates RNA integrity,
in accordance with the manufacturer’s instructions. For
each experimental condition, first-strand cDNA was
synthesized from 1 μg total RNA using the QuantiTect
Reverse Transcription Kit (Qiagen).
qRT-PCR was performed on an Eppendorf Realplex 4
Mastercycler using the Real MasterMix SYBR Green detec-
tion system (Eppendorf) in a total volume of 10 μl loaded
in triplicate. Primers for CD86 (NM_175862.4), COL I (N
M_000088), FN (NM_002026), TGFβ (NM_000660), αSM
A (NM_001613), S100A4 (NM_002961), CXCR2 (NM_0
0116829), CXCR4 (NM_00100854), CD11a (NM_001
11438), and β-actin (NM_001101, housekeeping gene) were
supplied by Primerdesign.
Gene expression values were calculated using the com-
parative ΔΔCT method and they corresponded to the
expression level (fold-increase) of the target gene com-
pared with the calibrator sample (untreated cells) taken
as the unit value by definition [32]. In each qRT-PCR
assay, the melting curve was performed to confirm the
specificity of the SYBR green assay.
Western blotting
Skin fibroblasts were cultured to 80% confluency and
treated as described in the “Cell culture and treat-
ments” section above. At the end of treatment (24
and 48 h), cells were lysed with NucleoSpin RNA/
protein (Macherey-Nagel). Protein quantification was
performed by the Bradford method. For each experi-
mental condition, 20 μg protein was separated by
electrophoresis on Tris-Glycine gel and transferred
onto Hybond-C-nitrocellulose membranes (Life Tech-
nologies Ltd.).
After 1 h in blocking solution (PBS 1× 0.1% triton-X,
and 5% nonfat powdered milk) membranes were incu-
bated overnight at 4 °C with the following primary anti-
bodies: anti-human COL I (dilution 1:400, Vinci-Biochem)
and FN (dilution 1:1000, Sigma-Aldrich). Membranes
were also incubated with primary horseradish peroxidase
(HRP)-conjugated antibody to human actin (dilution 1:10,
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000, Santa-Cruz Biotechnology) to confirm similar loading
of protein samples onto the gels and the efficiency of the
electrophoretic transfer.
Membranes were subsequently incubated with the
following secondary antibodies: anti-rabbit IgG for
COL I (dilution 1:2000, Cell Signaling Technology)
and anti-mouse IgG for FN (dilution 1:1000, Cell
Signaling Technology). Protein synthesis was detected
using the enhanced chemiluminescence system (Lumi-
nata Crescendo, Millipore). Densitometric analysis
was performed by UVITEC Analysis Software (UVI-
TEC Cambridge).
For each experimental condition, the values of
collagen type I (COL I) and FN synthesis were
normalized to those of the corresponding actin. The
resulting values of each treatment were compared
with those of the untreated cells (CNT; taken as the
unit value by definition) to obtain the level of protein
synthesis.
Statistical analysis
Statistical analysis was carried out by the nonpara-
metric Mann-Whitney U test to compare unpaired
treatment group data. Any p value below 0.05 was
considered statistically significant. The final results of
FACS, qRT-PCR, and Western blotting were the mean
of the results obtained from the independent experi-
ments performed on in-vitro cultures of fibrocytes
and skin fibroblasts isolated from each SSc patient




FACS analysis showed that at T0 the percentage of fibro-
cytes, identified as CD45+COL I+CXCR4+ cells, was 1.0
± 1.2% in SSc patients and 0.5 ± 0.2% in HSs (50% less)
(Fig. 1a). Moreover, in this fibrocyte population, the per-
centage of HLA-DR+ cells was very low (22.1 ± 21.1%
Fig. 1 Characterization of systemic sclerosis (SSc) and healthy subject (HS) fibrocytes at basal time (T0) and at 8 days of culture (T8). a FACS
analysis of SSc and HS fibrocytes, identified among the CD45+ cells, as CD45+, COL I+, CXCR4+, and relative HLA-DR and CD86 expression at T0; b
FACS analysis of SSc and HS fibrocytes, identified among the CD45+ cells, as CD45+, COL I+, CXCR4+, and relative HLA-DR and CD86 expression at
T0 and T8. c Quantitative RT-PCR analysis for CD86, αSMA, S100A4, TGFβ, and COL I gene expression of cultured SSc fibrocytes (T8), compared
with HS fibrocytes (T8), taken as the calibrator
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and 13.1 ± 4.7%, respectively), whereas the percentage of
CD86+ cells was higher in both SSc patients and HSs at
T0 (34.4 ± 21.4% and 68.9 ± 27.6%) (Fig. 1a).
At T8, fibrocytes showed an adherent spindle-shaped
morphology, and FACS analysis demonstrated that the per-
centage of CD45+COL I+CXCR4+ fibrocytes was signifi-
cantly higher in both SSc patients and in HSs compared
with T0 (up to 52.8 ± 27.1% vs. 1.0 ± 1.2% and up to 61.9 ±
24.4% vs. 0.5 ± 0.2%, respectively) (p < 0.01) (Fig. 1b).
At the same time, in this fibrocyte population, the
HLA-DR+ cells were significantly increased in SSc pa-
tients and HSs compared with T0 (90.1 ± 22.7% vs. 22.1
± 21.1% and 97.9 ± 1.9 vs 13.1 ± 4.7%, respectively)
(p < 0.01) (Fig. 1b).
Similarly, the percentage of CD86+ fibrocytes was
higher in SSc patients and HSs compared with T0 (60.4
± 25.6% vs. 34.4 ± 21.4%, and 90.7 ± 10.9% vs. 68.9 ±




At T8, in the absence of CTLA4-Ig, SSc fibrocytes
showed higher gene expression levels of CD86, αSMA,
S100A4, TGFβ, and COL I compared with HS fibrocytes
(Fig. 1c).
The SSc fibrocytes treated for 3 h with various con-
centrations of CTLA4-Ig (10, 50, 100, and 500 μg/ml)
did not show any significant variations in the gene ex-
pression levels of TGFβ, IL-1β, and CXCR2 compared
with CNT (Fig. 2a). In these cells, CD86 gene expression
decreased (not significantly) after treatment with
CTLA4-Ig 500 μg/ml (Fig. 2a).
Interestingly, the gene expression of COL I was signifi-
cantly lower in SSc fibrocytes treated with CTLA4-Ig
even at 10 μg/ml compared with CNT (p < 0.05) (Fig. 2a).
Of note, αSMA gene expression also decreased after
CTLA4-Ig treatment (significantly after CTLA4-Ig
10 μg/ml treatment, p < 0.05, and CTLA4-Ig 500 μg/ml
treatment, p < 0.01), whereas S100A4 gene expression
was significantly higher compared with CNT (p < 0.01)
excluding at the concentration of 500 μg/ml (Fig. 2a).
Moreover, while treatment with CTLA4-Ig 500 μg/ml
did not significantly reduce the gene expression of
CXCR4, it did significantly reduce that of CD11a as
compared with CNT (p < 0.05) (Fig. 2a).
HS fibrocytes
Unlike SSc fibrocytes, HS fibrocytes treated for 3 h with
various concentrations of CTLA4-Ig (10, 50, 100, and
500 μg/ml) did not show any significant modulation in
the gene expression levels of CD86 (Fig. 2b).
In addition, gene expression levels of TGFβ, CXCR2,
COL I, CXCR4, and CD11a remained unchanged after
CTLA4-Ig treatment compared with CNT, as did gene
expression of αSMA and S100A4 (Fig. 2b).
SSc fibroblasts
Cultured SSc fibroblasts showed very low gene expres-
sion levels of CD86 compared with cultured macro-
phages obtained from the PBMCs of SSc patients, which
Fig. 2 Quantitative RT-PCR analysis for TGFβ, IL-1β, CXCR2, CD86, COL I, αSMA, S100A4, CXCR4, and CD11a gene expression in cultures of
systemic sclerosis (SSc) and healthy subject (HS) fibrocytes after 3 h of CTLA4-Ig treatment. Quantitative RT-PCR analysis for TGFβ, IL-1β, CXCR2,
CD86, COL I, αSMA, S100A4, CXCR4, and CD11a gene expression in cultures of SSc fibrocytes (a) and HS fibrocytes (b) either untreated (CNT) or
treated for 3 h with CTLA4-Ig at various doses (10, 50, 100, and 500 μg/ml). *p < 0.05, **p < 0.01
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were taken as positive controls for CD86 expression
(Additional file 1).
Nevertheless, cultured SSc fibroblasts treated for 24 h
with CTLA4-Ig (10, 50, 100, and 500 μg/ml) did not
show any significant differences in gene expression levels
of CD86 compared with CNT (a nonsignificant increase
after treatment with CTLA4-Ig 10 μg/ml was observed)
(Fig. 3a). At the same time, gene expression of COL I
and FN was higher only in the cultured SSc fibroblasts
which had been treated with the lowest concentration of
CTLA4-Ig (10 μg/ml) (Fig. 3a).
In addition, in these cultured CTLA4-Ig-treated SSc
cells, the gene expression levels of αSMA, TGFβ. and
S100A4 were higher compared with CNT (significantly
for αSMA and S100A4; p < 0.01) (Fig. 3a).
On the other hand, the cultured SSc fibroblasts treated
for 48 h with CTLA4-Ig (10, 50, 100, and 500 μg/ml)
did not show any significant modulation in the gene ex-
pression levels of CD86, FN, αSMA, TGFβ, and S100A4
compared with CNT, whereas the gene expression of
COL I was significantly downregulated by the highest
dose of CTLA4-Ig (p < 0.05) (Fig. 3b).
HS fibroblasts
Cultured HS fibroblasts treated with CTLA4-Ig for 24 h
showed a significant decrease in the gene expression of
CD86, although this was limited to the highest dose
(500 μg/ml) compared with CNT (p < 0.05) (Fig. 3a).
Of note, the gene expression of TGFβ and S100A4
was significantly reduced by the higher doses of
CTLA4-Ig (p < 0.05 after 100 and 500 μg/ml for TGFβ;
p < 0.05 after 500 μg/ml for S100A4) (Fig. 3a).
Similar to the results obtained after 24 h of CTLA4-Ig
treatment, cultured HS fibroblasts showed a significant
decrease in the gene expression levels of CD86 com-
pared with CNT after 48 h of treatment with CTLA4-Ig,
though this was limited to the highest dose (500 μg/ml)
(p < 0.05) (Fig. 3b).
After 48 h of treatment with the highest dose of
CTLA4-Ig (500 μg/ml), gene expression of TGFβ and
S100A4 was significantly reduced compared with CNT
(both p < 0.05) (Fig. 3b).
Gene expression of COL I, FN, and αSMA was un-
changed after both 24 and 48 h of CTLA4-Ig treatment
in cultured HS fibroblasts (Fig. 3a, b).
Fig. 3 Quantitative RT-PCR analysis for CD86, COL I, FN, αSMA, TGFβ, and S100A4 gene expression in cultured systemic sclerosis (SSc) and healthy
subject (HS) fibroblasts after 24 and 48 h of CTLA4-Ig treatments. Quantitative RT-PCR analysis for CD86, COL I, FN, αSMA, TGFβ, and S100A4 gene
expression in cultures of SSc and HS fibroblasts either untreated (CNT) or treated for 24 h (a) and 48 h (b) with CTLA4-Ig at various doses (10, 50,
100, and 500 μg/ml). *p < 0.05, **p < 0.01
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Western blotting
The protein expression of COL I and FN in cultured SSc
and HS fibroblasts was unchanged even after treatment
with CTLA4-Ig at both 24 and 48 h compared with
CNT (Fig. 4).
Discussion
The present study reports for the first time that SSc cir-
culating fibrocytes show an increased basal expression of
αSMA and COL I compared with HS fibrocytes, suggest-
ing their possible propensity for transition into activated
myofibroblasts which are key cells involved in both tis-
sue repair and fibrosis. Moreover, SSc circulating fibro-
cytes show a higher gene expression of CD86 and seem
to be more responsive to treatment with the CTLA4-Ig
fusion protein compared with the skin fibroblasts ob-
tained from the same SSc patients.
This study also confirms that the percentage of circulat-
ing fibrocytes, characterized as CD45+COL I+CXCR4+ cells,
was at least twice as high in SSc patients compared with
HSs, although these cells are a minor component of the cir-
culating pool of cells [11, 16, 33].
On the basis of these characteristics, we observed that
once circulating fibrocytes are cultured in vitro they be-
come adherent, develop a spindle-shaped morphology,
and maintain the expression of key fibrocyte phenotype
markers (CD45, COL I, and CXCR4), with a further in-
crease in CD86 and HLA-DRII expression.
The interaction between the CTLA4-Ig fusion molecule
(abatacept) and CD86 expressed on circulating fibrocytes
is believed to alter and interfere with the function of these
cells under pathological conditions, such as SSc, and in
particular with their activation and differentiation into fi-
broblasts/myofibroblasts. The decrease in the gene ex-
pression of the main phenotypic markers of activated
fibrocytes (COL I and CXCR4), together with the de-
creased gene expression of the myofibroblast phenotype
marker αSMA induced by CTLA4-Ig treatment, suggests
a possible downregulatory effect on the fibrocyte-myofi-
broblast transition process. It is interesting to note that
these effects were evident in SSc circulating fibrocytes, but
they were not observed in the HS circulating fibrocytes.
It is believed that, in response to injurious and inflam-
matory stimuli, human CD45+COL I+CXCR4+ fibrocytes
traffic through the bloodstream and may be recruited
into, and activated within, the injured and inflamed tis-
sues where the chemokine receptors CXCR4 and CCR7
are reported to be pivotal [10, 14]. Of note, the ability of
CTLA4-Ig to trigger a decrease in the expression of
CXCR4 and CD11a adhesion/migration molecules on
SSc circulating fibrocytes may suggest its possible action
in interfering with trafficking and migration of these
cells into inflammatory/altered sites [10, 14].
Fibrocytes can also function as APCs for the activation
of CD8+ T cells by expressing major histocompatibility
complex class I and II molecules and the costimulatory
proteins CD80 and CD86 [20]. By binding to SSc circulat-
ing fibrocytes expressing CD86, CTLA4-Ig might interfere
with their APC activity and could likely prevent the activa-
tion of T lymphocytes, as already demonstrated for other
cellular targets (dendritic cells, B lymphocytes, macro-
phages, osteoclasts, endothelial cells) [21, 24, 34–37].
It is possible that, in SSc, circulating fibrocytes are
already activated by the immune-inflammatory response
Fig. 4 Western blot analysis of COL I and FN on cultured systemic sclerosis (SSc) and healthy subject (HS) fibroblasts after 24 and 48 h of CTLA4-
Ig treatment. Western blotting analysis of COL I and FN in cultured SSc and HS fibroblasts. Western blotting of COL I and FN, and related
densitometric analysis on cultured SSc and HS fibroblasts either untreated (CNT) or treated for 24 h (a) and 48 h (b) with various concentrations
of CTLA4-Ig (line 1: CNT, calibrator; line 2: CTLA4-Ig 10 μg/ml: line 3: CTLA4-Ig 50 μg/ml; line 4: CTLA4-Ig 100 μg/ml; line 5: CTLA4-Ig 500 μg/ml;
line 6: Molecular Weight)
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associated with the disease, and that they are more
responsive to other protein interactions, in particular to
CTLA4-Ig, as compared with HS circulating fibrocytes.
A limitation of these in-vitro experiments relates to
the small number of circulating fibrocytes that can be
obtained from SSc patients and from HSs; therefore,
larger samples are needed to confirm the obtained data.
A further study evaluating SSc patients with diffuse skin
involvement is already in progress. Very preliminary data
obtained from in-vitro experiments on circulating fibro-
cytes isolated from only two patients, and treated with
CTLA4-Ig, seem to show results similar to that de-
scribed in our study.
Concerning fibroblasts, CD86 gene expression was
found to be very low in cultured SSc fibroblasts, contrary
to that found in circulating fibrocytes from the same pa-
tients, as already reported for murine fibroblasts [38]. As a
possible consequence of the limited interaction with
CD86, in the present short-term study (24 and 48 h) the
CTLA4-Ig treatment did not induce a decrease in the
ECM protein synthesis (COL I and FN) in cultured SSc fi-
broblasts or in HS fibroblasts.
A further study evaluating SSc patients with diffuse
cutaneous involvement (dcSSc) is already in progress.
Very preliminary data obtained from in-vitro experi-
ments on circulating fibrocytes isolated from only two
dcSSc patients, and treated with CTLA4-Ig, seem to
show results similar to those described in lcSSc.
In addition, the histopathological literature in SSc
attests that both the limited cutaneous as well as the
diffuse cutaneous subset are characterized by the
presence of myofibroblasts [39]. Hence, our study design
should be equally applicable in limited cutaneous as well
as diffuse cutaneous SSc.
Of note, the CTLA4-Ig treatment (at high doses)
seems to induce a decrease in the TGFβ gene expression
that can already be observed after 24 h of treatment;
this, however, is limited to the cultured HS fibroblasts.
Conclusions
In conclusion, circulating fibrocytes seem to be more re-
sponsive to CTLA4-Ig treatment than skin fibroblasts iso-
lated from the same SSc patients characterized by limited
cutaneous involvement. Thus, a new therapeutic option
for abatacept in SSc treatment should be taken into con-
sideration based on its possible antifibrotic effect.
Therefore, as described for the first time in the present
study, the higher efficacy exerted at the gene expression
level by CTLA4-Ig in cultured circulating fibrocytes versus
cultured skin fibroblasts/myofibroblasts isolated from the
same SSc patients may represent a new approach for early
intervention, acting on progenitor cells before their final
homing and differentiation into active myofibroblasts.
Additional file
Additional file 1: Figure S1. CD86 gene expression levels in cultured
SSc fibroblasts. Bar graph of quantitative RT-PCR analysis for CD86 gene
expression in cultures of SSc fibroblasts, compared with SSc macrophages,
taken as calibrator. (TIF 180 kb)
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real-time polymerase chain reaction; S100A4: Fibroblast-specific protein-1;
SMA: Smooth muscle actin; SSc: Systemic sclerosis; Tx: Day x; TGF: Transforming
growth factor; TNF: Tumor necrosis factor; VEGFR: Vascular endothelial growth
factor receptor
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